
Sign up to save your podcasts
Or


Professor Marc Riedl joins us to discuss two trials testing oral deucrictibant for hereditary angioedema attacks: one testing deucrictibant as on-demand therapy to treat attacks and the other testing deucrictibant for prophylaxis of attacks.
Click here to read the full articles:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00341-2/fulltext
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00004-9/fulltext
Continue this conversation on social!
By The Lancet GroupProfessor Marc Riedl joins us to discuss two trials testing oral deucrictibant for hereditary angioedema attacks: one testing deucrictibant as on-demand therapy to treat attacks and the other testing deucrictibant for prophylaxis of attacks.
Click here to read the full articles:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00341-2/fulltext
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00004-9/fulltext
Continue this conversation on social!

22 Listeners

0 Listeners

0 Listeners

3 Listeners

1 Listeners

0 Listeners

1 Listeners

0 Listeners

0 Listeners

1 Listeners

1 Listeners

1 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners